A Randomized, Pilot Study To Assess The Efficacy And Safety Of Curcumin In Patients With Active Rheumatoid Arthritis

Effect Decrease
Values DAS-28. Within group. Curcumin: before 28 ± 23.7, after 24.86 ± 17.7. Diclofenac sodium: before 27.08 ± 17.1, after 24.75 ± 13.5. Combination: before 28.75 ± 20.9, after 24.92 ± 22.6
Trial Design Randomized trial
Trial Length 1-6 months
Number of Subjects 45
Sex Both Genders
Age Range 18-29, 30-44, 45-64, 65+
Body Types Obese, Overweight, Average, Underweight
Notes for this study:
In a randomized, single-blind pilot trial, 45 participants with rheumatoid arthritis were assigned to take 500 mg of curcumin (BCM-95), 50 mg of diclofenac sodium, or the combination daily for 8 weeks.

The primary outcome was an evaluation of rheumatoid arthritis symptoms (DAS28). All groups saw a large statistically significant (within-group) reduction in DAS. However, there weren't any notable differences between groups for the side of effect.

Pain on the visual analog scale declined substantially in all groups, and the within-group changes were statistically significant. The curcumin and combination groups saw a somewhat greater reduction than the diclofenac sodium group, but no between-group statistics were provided. The decrease in symptoms according to the American College Of Rheumatology assessment was statistically significant for all groups, and comparable for all groups, with no between-group statistics provided.

C-reactive protein levels were reduced in the curcumin and combination groups, with the curcumin group seeing the largest reduction, and the diclofenac sodium group not seeing any reduction. Erythrocyte sedimentation rate, declined somewhat in all groups, but the within-group changes weren't statistically significant, and there weren't any notable differences between groups.

The curcumin group didn't experience a notable rate of adverse events or see worrying changes in blood tests.

Full details on all 2 studies are available to Examine Plus members.

Already a member? Login now to access.